HRP20140915T1 - Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo - Google Patents

Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo Download PDF

Info

Publication number
HRP20140915T1
HRP20140915T1 HRP20140915AT HRP20140915T HRP20140915T1 HR P20140915 T1 HRP20140915 T1 HR P20140915T1 HR P20140915A T HRP20140915A T HR P20140915AT HR P20140915 T HRP20140915 T HR P20140915T HR P20140915 T1 HRP20140915 T1 HR P20140915T1
Authority
HR
Croatia
Prior art keywords
seq
antibody
ngf
amino acid
pain
Prior art date
Application number
HRP20140915AT
Other languages
English (en)
Inventor
John Powell
Mark Maginn
Duncan Casson
Andrea Best
Jerry A. Hall
Wei Liu
Sandeep Dutta
Original Assignee
Abbvie Research B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Research B.V. filed Critical Abbvie Research B.V.
Publication of HRP20140915T1 publication Critical patent/HRP20140915T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Claims (16)

1. Protutijelo koje služi protiv faktora rasta živaca (Nerve Growth Factor - NGF), naznačeno time, da obuhvaća: (i) varijabilno područje jakog lanca, koje sadrži CDR1, CDR2 i CDR3, gdje oni imaju prema svakom pojedinačno, aminokiselinske sekvence SEQ ID NO: 3, SEQ ID NO:4 i SEQ ID NO:5, (ii) varijabilno područje slabog lanca, koje sadrži CDR1, CDR2 i CDR3, gdje oni imaju prema svakom pojedinačno, aminokiselinske sekvence SEQ ID NO: 6, SEQ ID NO:7 i SEQ ID NO:8, i (iii) konstantno područje humanog IgG4, koje sadrži aminokiselinsku sekvencu SEQ ID NO:10.
2. Protutijelo prema zahtjevu 1, naznačeno time, da obuhvaća varijabilno područje jakog lanca, koje sadrži aminokiselinsku sekvencu SEQ ID NO:1 i varijabilno područje slabog lanca, koje sadrži aminokiselinsku sekvencu SEQ ID NO:2.
3. Protutijelo prema zahtjevu 1 ili 2, naznačeno time, da obuhvaća jaki lanac koji sadrži aminokiselinsku sekvencu SEQ ID NO:13 i slabi lanac koji sadrži aminokiselinsku sekvencu SEQ ID NO:16.
4. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time, da je to humanizirano protutijelo.
5. Farmaceutski sastav, naznačen time, da obuhvaća anti-NGF protutijelo prema bilo kojem od zahtjeva 1 do 4 i farmaceutski prihvatljiv nosač.
6. Garnitura, naznačena time, da obuhvaća anti-NGF protutijelo prema bilo kojem od zahtjeva 1 do 4.
7. Nukleinska kiselina, naznačena time, da kodira jaki lanac protutijela prema bilo kojem od zahtjeva 1 do 4.
8. Nukleinska kiselina prema zahtjevu 7, naznačena time, da nadalje kodira slabi lanac protutijela prema bilo kojem od zahtjeva 1 do 4.
9. Vektor ekspresije, naznačen time, da obuhvaća nukleinsku kiselinu prema zahtjevu 7 ili 8.
10. Vektor ekspresije prema zahtjevu 9, naznačen time, da obuhvaća SEQ ID NO:11 i SEQ ID NO:14.
11. Stanica domaćina, naznačena time, da obuhvaća vektor ekspresije prema zahtjevu 9 ili 10.
12. Postupak ekspresije anti-NGF protutijela prema zahtjevu 1, naznačen time, da obuhvaća kultiviranje stanice domaćina iz zahtjeva 11.
13. Anti-NGF protutijelo prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da se upotrebljava u postupku liječenja bolova.
14. Uporaba anti-NGF protutijela prema bilo kojem od zahtjeva 1 do 4, naznačena time, da je za proizvodnju lijeka za liječenje bolova.
15. Protutijelo za uporabu prema zahtjevu 13 ili uporaba prema zahtjevu 14, naznačeno/a time, da bolovi su bolovi kod osteoartritisa.
16. Protutijelo za uporabu prema zahtjevu 13 ili uporaba prema zahtjevu 14, naznačeno/a time, da bolovi su kronični bolovi donjeg dijela leđa (bolovi u križima).
HRP20140915AT 2009-05-04 2014-09-24 Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo HRP20140915T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17522809P 2009-05-04 2009-05-04
US22725109P 2009-07-21 2009-07-21
US23881309P 2009-09-01 2009-09-01
US25231409P 2009-10-16 2009-10-16
PCT/IB2010/001210 WO2010128398A1 (en) 2009-05-04 2010-05-04 Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Publications (1)

Publication Number Publication Date
HRP20140915T1 true HRP20140915T1 (hr) 2014-12-05

Family

ID=43030513

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140915AT HRP20140915T1 (hr) 2009-05-04 2014-09-24 Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo

Country Status (31)

Country Link
US (2) US8435523B2 (hr)
EP (1) EP2448970B1 (hr)
JP (2) JP5898064B2 (hr)
KR (1) KR20120088550A (hr)
CN (1) CN102459337B (hr)
AR (1) AR076650A1 (hr)
AU (1) AU2010244133B2 (hr)
BR (1) BRPI1014445A8 (hr)
CA (1) CA2761203A1 (hr)
CL (1) CL2011002765A1 (hr)
CO (1) CO6470819A2 (hr)
CR (1) CR20110629A (hr)
DK (1) DK2448970T3 (hr)
DO (1) DOP2011000337A (hr)
EC (1) ECSP11011502A (hr)
ES (1) ES2514319T3 (hr)
HK (1) HK1170508A1 (hr)
HR (1) HRP20140915T1 (hr)
IL (1) IL216128A (hr)
MX (1) MX2011011728A (hr)
NZ (1) NZ596839A (hr)
PE (1) PE20121540A1 (hr)
PL (1) PL2448970T3 (hr)
PT (1) PT2448970E (hr)
RU (1) RU2549679C2 (hr)
SG (1) SG175436A1 (hr)
SI (1) SI2448970T1 (hr)
TW (1) TWI486171B (hr)
UA (1) UA104890C2 (hr)
UY (1) UY32608A (hr)
WO (1) WO2010128398A1 (hr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CA2695997C (en) 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
NZ602054A (en) 2010-03-17 2014-10-31 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
ES2720136T3 (es) * 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
US20140170136A1 (en) 2011-05-06 2014-06-19 Nvip Pty Ltd. Anti-nerve growth factor antibodies and methods of preparing and using the same
MX351273B (es) 2011-08-11 2017-10-06 Astellas Pharma Inc Nuevo anticuerpo anti-ngf humano.
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
KR200480634Y1 (ko) 2015-04-14 2016-06-16 한전케이피에스 주식회사 긴급복구용 윈치의 고정장치
WO2016190263A1 (ja) 2015-05-22 2016-12-01 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
IT201700066486A1 (it) * 2017-06-15 2018-12-15 Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
US20210147529A1 (en) 2018-05-15 2021-05-20 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof
MX2019012352A (es) 2018-10-15 2020-08-20 Avent Inc Composiciones, sistemas, kits y metodos para ablacion neural.
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
CN110583625A (zh) * 2019-09-17 2019-12-20 深圳大学 一种脐带储存液
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Ampsource Biopharma Shanghai Inc. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
CN112625128B (zh) * 2020-08-06 2022-11-08 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
CN114729330A (zh) 2021-07-30 2022-07-08 成都优洛生物科技有限公司 一种重组cho细胞、其构建方法、利用其的检测系统和方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0559834A1 (en) 1990-11-30 1993-09-15 Abbott Laboratories Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DK1255824T3 (da) 1999-08-06 2010-07-19 S I S S A Scuola Internaz Supe Transgene mus til undersøgelse af neurodegenerative syndromer
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
AU2002308722B2 (en) 2001-05-30 2007-05-17 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003284010A1 (en) 2002-10-04 2004-05-04 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
DE60335957D1 (de) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
CA2502904C (en) * 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1589988A2 (en) 2002-12-20 2005-11-02 Neuronicon ApS Modulation of activity of neurotrophins
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
BRPI0407375A (pt) 2003-02-19 2006-02-07 Rinat Neuroscience Corp Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
ES2355558T3 (es) * 2003-02-19 2011-03-28 Rinat Neuroscience Corp. Procedimiento para tratar el dolor administrando un antagonista del factor de crecimiento neuronal y un aine y la composición que contiene los mismos.
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
GEP20104887B (en) 2003-07-15 2010-02-10 Medarex Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
HUE037549T2 (hu) 2004-04-07 2018-09-28 Rinat Neuroscience Corp Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
KR20070085886A (ko) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 감소된 면역원성의 ｉｌ-7 변이체
KR101298383B1 (ko) 2005-01-24 2013-08-20 엘란 파마 인터내셔널 리미티드 Ｎｇｆ에 대한 특이적 결합 멤버
AU2006249087B2 (en) 2005-05-20 2012-05-17 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CA2695997C (en) 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
WO2011000020A1 (en) 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
NZ602054A (en) 2010-03-17 2014-10-31 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions

Also Published As

Publication number Publication date
UY32608A (es) 2010-12-31
MX2011011728A (es) 2012-04-19
ES2514319T3 (es) 2014-10-28
SI2448970T1 (sl) 2014-11-28
TWI486171B (zh) 2015-06-01
US20130295112A1 (en) 2013-11-07
CN102459337A (zh) 2012-05-16
CR20110629A (es) 2012-05-28
JP2012525838A (ja) 2012-10-25
AU2010244133A1 (en) 2011-12-15
JP5898064B2 (ja) 2016-04-06
PL2448970T3 (pl) 2014-12-31
HK1170508A1 (en) 2013-03-01
DK2448970T3 (da) 2014-10-06
ECSP11011502A (es) 2012-04-30
PE20121540A1 (es) 2012-12-22
NZ596839A (en) 2014-01-31
SG175436A1 (en) 2011-12-29
JP2016026221A (ja) 2016-02-12
KR20120088550A (ko) 2012-08-08
US20100278839A1 (en) 2010-11-04
AU2010244133B2 (en) 2015-07-23
CL2011002765A1 (es) 2012-07-20
WO2010128398A1 (en) 2010-11-11
CA2761203A1 (en) 2010-11-11
US9447181B2 (en) 2016-09-20
RU2549679C2 (ru) 2015-04-27
TW201043246A (en) 2010-12-16
US8435523B2 (en) 2013-05-07
CN102459337B (zh) 2015-05-20
BRPI1014445A2 (pt) 2016-11-29
IL216128A0 (en) 2012-01-31
BRPI1014445A8 (pt) 2018-01-09
IL216128A (en) 2015-10-29
AR076650A1 (es) 2011-06-29
DOP2011000337A (es) 2012-02-15
EP2448970B1 (en) 2014-07-09
CO6470819A2 (es) 2012-06-29
EP2448970A1 (en) 2012-05-09
PT2448970E (pt) 2014-10-20
UA104890C2 (uk) 2014-03-25
RU2011149263A (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
HRP20140915T1 (hr) Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
HRP20211594T1 (hr) Anti-pd1 protutijela i načini uporabe
EA201290189A1 (ru) Человеческие нейтрализующие антитела анти-ngf в качестве селективных ингибиторов метаболических путей фактора роста нервов
HRP20161689T1 (hr) Bispecifične vezne molekule koje se vežu na vegf i ang2
HRP20190817T1 (hr) Ang2-vezujuće molekule
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
HRP20160131T1 (hr) Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba
UA117294C2 (uk) Імунокон'югат
JP2014169326A5 (hr)
HRP20151215T1 (hr) Anti-nr10 protutijela i njihova uporaba
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
BR112013020338A2 (pt) proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
JP2016527273A5 (hr)
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA201591792A1 (ru) Улучшенные композиции для лечения мышечной дистрофии
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
AR080794A1 (es) Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
BRPI0816014A2 (pt) Anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
MX2013002379A (es) Moleculas de union a vegf.
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)